Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

ORLANDO, FL USA (UroToday.com) - The objective of this multi-institutional study was to determine the comparative effectiveness and cost-effectiveness of abiraterone acetate (AA) versus enzalutamide (ENZ). They used population, intervention, comparison, and outcomes (PICO) to evaluate the comparability of the pivotal phase 3 clinical trials: COU-AA-301 for AA and AFFIRM for ENZ. Bucher method and Bayesian statistics was used to conduct an indirect treatment comparison. A survival-based Markov cohort model with 3 health states (progression-free, progressed, and death) was developed to estimate cost-effectiveness over a lifetime horizon. For a 30-day supply of AA and ENZ, the average wholesale prices were $7674 and $8940, respectively. They utilized one-way sensitivity analyses for all probability, utility, and cost values incorporated into the model.

auaAfter accounting for important differences in comparators and background treatments, the results of indirect treatment comparison showed no significant difference in overall survival for AA compared to ENZ. In the base case of the economic analysis, AA was found to provide an annual cost savings of $13,322 per patient and this is primarily due to higher acquisition costs of ENZ. Quality-adjusted life years gained were comparable for AA and ENZ. These results were supported by sensitivity analyses. AA and ENZ are 2 treatment options for patients with metastatic castration-resistant prostate cancer. Presently, there is great interest in understanding the relative clinical and economic value of these therapies. The results of this indirect treatment comparison shows that both AA and ENZ can have similar efficacy in terms of OS in post chemotherapy mCRPC patients; However, it appears that AA is more cost effective compared to ENZ.

Click HERE to view the poster from this session

Presented by Melissa Thompson at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Burlington, ON Canada

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Calendar
Upcoming urology industry events
August 1-5, 2018 / Sheraton Philadelphia Society Hill Hotel
SUFU Research Foundation Resident Preceptorship 2018
August 3-4, 2018 / Hyatt Regency Washington on Capitol Hill
Best of ASCO 2018 - Washington, DC
August 10-11, 2018 / The Palmer House Hilton, Chicago, IL
Best of ASCO 2018 - Chicago, IL
August 28-31, 2018 / ICS 2018
International Continence Society 2018
Journals
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor